AIM: To determine whether the telomerase activity is related to the Microsatellite instability (MSI) genetic pathway and whether it means a difference in the survival. METHODS: The population consisted of 97 colorectal cancer patients. MSI determination was performed in accordance with the NCI criteria using PCR and Genescan. Telomerase activity was determined by the TRAP-assay, an ELISA procedure based on the amplification of telomeric repeat sequences. RESULTS: 6.2% showed high MSI (MSI-H), 10.3% showed low MSI (MSI-L) and 83.5% did not show this alteration (MSS). Positive telomerase activity was detected in 92.8% of the patients. 83.3% of MSI-H tumors showed positive telomerase against 93.8% of MSS tumors. In the overall survival analysis the absence of telomerase activity conferred a better prognosis. CONCLUSION: Previous works have shown that tumors which develop via the MSI pathway present a better prognosis. No link between telomerase activity and MSI status is observed, although sample sizes are small. Patients with telomerase negative tumors had better overall survival than patients with telomerase positive tumors.
AIM: To determine whether the telomerase activity is related to the Microsatellite instability (MSI) genetic pathway and whether it means a difference in the survival. METHODS: The population consisted of 97 colorectal cancerpatients. MSI determination was performed in accordance with the NCI criteria using PCR and Genescan. Telomerase activity was determined by the TRAP-assay, an ELISA procedure based on the amplification of telomeric repeat sequences. RESULTS: 6.2% showed high MSI (MSI-H), 10.3% showed low MSI (MSI-L) and 83.5% did not show this alteration (MSS). Positive telomerase activity was detected in 92.8% of the patients. 83.3% of MSI-H tumors showed positive telomerase against 93.8% of MSS tumors. In the overall survival analysis the absence of telomerase activity conferred a better prognosis. CONCLUSION: Previous works have shown that tumors which develop via the MSI pathway present a better prognosis. No link between telomerase activity and MSI status is observed, although sample sizes are small. Patients with telomerase negative tumors had better overall survival than patients with telomerase positive tumors.
Authors: Rika Kawanishi-Tabata; Francisco Lopez; Sam Fratantonio; Nam Kim; John Goldblum; Raymond Tubbs; Paul Elson; Ian Lavery; Ronald M Bukowski; Ram Ganapathi; Mahrukh K Ganapathi Journal: Cancer Date: 2002-11-01 Impact factor: 6.860
Authors: M Teresa Sanz-Casla; Marta Vidaurreta; Dolores Sanchez-Rueda; M Luisa Maestro; Manuel Arroyo; F Javier Cerdán Journal: Onkologie Date: 2005-11
Authors: Wade S Samowitz; Carol Sweeney; Jennifer Herrick; Hans Albertsen; Theodore R Levin; Maureen A Murtaugh; Roger K Wolff; Martha L Slattery Journal: Cancer Res Date: 2005-07-15 Impact factor: 12.701
Authors: C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: Charles N Landen; Al Klingelhutz; Jeremy E Coffin; Joel I Sorosky; Anil K Sood Journal: Cancer Biol Ther Date: 2004-12-14 Impact factor: 4.742
Authors: Cristina Frías; Alberto Morán; Carmen de Juan; Paloma Ortega; Tamara Fernández-Marcelo; Andrés Sánchez-Pernaute; Antonio José Torres; Eduardo Díaz-Rubio; Manuel Benito; Pilar Iniesta Journal: World J Gastrointest Oncol Date: 2009-10-15
Authors: Georgios D Ayiomamitis; George Notas; Apostolos Zaravinos; Ioannis Drygiannakis; Maria Georgiadou; Ourania Sfakianaki; Niki Mastrodimou; Kyriaki Thermos; Elias Kouroumalis Journal: Oncoscience Date: 2014-06-30
Authors: Brooke R Druliner; Xiaoyang Ruan; Ruth Johnson; Diane Grill; Daniel O'Brien; Tsung-Po Lai; Shahrooz Rashtak; Donna Felmlee-Devine; Jill Washechek-Aletto; Andrei Malykh; Thomas Smyrk; Ann Oberg; Hongfang Liu; Jerry W Shay; David A Ahlquist; Lisa A Boardman Journal: Clin Transl Gastroenterol Date: 2016-09-01 Impact factor: 4.488
Authors: R Bertorelle; M Briarava; E Rampazzo; L Biasini; M Agostini; I Maretto; S Lonardi; M L Friso; C Mescoli; V Zagonel; D Nitti; A De Rossi; S Pucciarelli Journal: Br J Cancer Date: 2013-01-15 Impact factor: 7.640